Restoring Vision for Children Who Deserve to See
Lumina Therapeutics is turning a rare diagnosis into a story of hope — and we want you involved.
Explore the OpportunityPhoto by Kampus Production on Pexels
The Progress Speaks for Itself
Why Lumina Therapeutics Is a Story Worth Knowing
A Problem That Couldn't Wait
Thousands of children are born with a rare genetic eye condition that steadily robs them of sight. Existing treatments manage symptoms — Lumina's gene therapy targets the root cause, offering the possibility of lasting restored vision.
Explore the Opportunity →What We're Actually Doing About It
Our Phase II clinical trial has delivered statistically significant improvements in visual acuity. We're not promising a cure — we're showing you the data, the milestones, and the real children whose lives are already changing.
Explore the Opportunity →Why You Can Trust This Team
Lumina Therapeutics was built by scientists and operators who've been here before. With rigorous peer-reviewed data, a clear regulatory pathway, and a mission that never loses sight of the patient, we are the rare kind of company that earns confidence.
Explore the Opportunity →Our Journey, Step by Step
Lumina Therapeutics established its gene therapy platform and completed foundational safety studies, confirming tolerability in early models with no significant adverse events.
Phase II cohort data showed 90% efficacy in restoring light sensitivity and statistically significant improvements in visual acuity — a milestone that validated our core scientific thesis.
We are actively enrolling patients for expanded clinical trials and closing our Series B funding round — two parallel milestones that will carry this therapy to the children who need it most.
With Series B secured, Lumina Therapeutics will scale manufacturing, advance toward regulatory submission, and position for a commercialization pathway that changes the standard of care globally.
What People Are Saying About Lumina
"The Phase II data Lumina presented was among the most compelling I've seen in rare pediatric indications. The efficacy signal is real, and the team clearly understands the regulatory landscape. This is the kind of opportunity that comes along once in a decade."
Dr. Evelyn Reed